NASDAQ · LIXT
Lixte Biotechnology Holdings, Inc.
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
Loading market information…
NASDAQ · LEXX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lexaria Bioscience Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lexaria Bioscience Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $174.00K+16.0% vs estimate |
| Q1 2025 | Jan 10, 2025 | -$2.40-33.33% vs estimate | $184.00K+84.0% vs estimate |
|---|
| Q4 2024 | Nov 26, 2024 | -$2.25-36.36% vs estimate | $92.00K-54.0% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$3.31-$0.19 (-5.43%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.35% below the high.
$0.89-$0.06 (-6.32%)
Allarity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.63% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$0.80-$0.02 (-2.22%)
Hoth Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.29% below the high.
$1.89+$0.04 (+2.16%)
Processa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.56% below the high.
$0.11+$0.01 (+10.0%)
CASI Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.86% below the high.
